{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:45:06Z","timestamp":1791650706057,"version":"4.3.4"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>\n                    The polymorphic CYP2D6 enzyme plays a pivotal role in the metabolism of approximately 25% of clinically prescribed drugs. However, the impact of specific genetic variants on the interindividual variability in CYP2D6\u2010mediated drug metabolism remains insufficiently quantified. This translational study sought to address this gap by analyzing the genotypes and phenotypes of patients in two large clinical cohorts, focusing on the metabolism of the CYP2D6 substrates risperidone and desmethyltamoxifen. The analysis incorporated novel polymorphic haplotypes and substrate\u2010specific differences among the CYP2D6.1, CYP2D6.2, and CYP2D6.35 enzyme variants. The study revealed that CYP2D6.2 and CYP2D6.35 exhibit reduced metabolic capacity for these substrates, both\n                    <jats:italic>in vivo<\/jats:italic>\n                    and in an\n                    <jats:italic>in vitro<\/jats:italic>\n                    expression model. This was evidenced by decreased catalytic turnover (Kcat), decreased substrate affinity, and altered substrate docking. Furthermore, novel polymorphic haplotypes on the\n                    <jats:italic>CYP2D6*1, CYP2D6*2,<\/jats:italic>\n                    and\n                    <jats:italic>CYP2D6*35<\/jats:italic>\n                    backgrounds were identified, each associated with a 30\u201340% increase in CYP2D6 activity. Incorporating these findings into prediction equations significantly improved the genetic prediction accuracy (\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    ) for CYP2D6\u2010mediated metabolism of desmethyltamoxifen from 59% to 71% and risperidone, also metabolized by CYP3A4, from 42% to 46%. These results highlight the importance of accounting for drug\u2010specific interactions with enzyme variants and integrating distinct polymorphic haplotypes into CYP pharmacogenomic models and guidelines for better translation into clinical practice.\n                  <\/jats:p>","DOI":"10.1002\/cpt.3680","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:33:50Z","timestamp":1745328830000},"page":"218-231","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account"],"prefix":"10.1002","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6646-4551","authenticated-orcid":false,"given":"Inger","family":"Johansson","sequence":"first","affiliation":[{"name":"Section of Pharmacogenetics, Department of Physiology and Pharmacology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6208-1136","authenticated-orcid":false,"given":"Emmanouella M.","family":"Xanthopoulou","sequence":"additional","affiliation":[{"name":"Section of Pharmacogenetics, Department of Physiology and Pharmacology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-5444","authenticated-orcid":false,"given":"Yitian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Section of Pharmacogenetics, Department of Physiology and Pharmacology Karolinska Institutet  Stockholm Sweden"},{"name":"Center for Molecular Medicine Karolinska Institutet and University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2073-5648","authenticated-orcid":false,"given":"Anabel","family":"Sanchez\u2010Spitman","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3344-6896","authenticated-orcid":false,"given":"Maaike","family":"van der Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-275X","authenticated-orcid":false,"given":"Birgit M.","family":"Wollmann","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2662-8504","authenticated-orcid":false,"given":"Elisabet","family":"St\u00f8rset","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"},{"name":"Department of Pharmacy University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-1383","authenticated-orcid":false,"given":"Henk\u2010Jan","family":"Guchelaar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-2751","authenticated-orcid":false,"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"},{"name":"Department of Pharmacy University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5296-4245","authenticated-orcid":false,"given":"Marin M.","family":"Jukic","sequence":"additional","affiliation":[{"name":"Section of Pharmacogenetics, Department of Physiology and Pharmacology Karolinska Institutet  Stockholm Sweden"},{"name":"Department of Physiology, Faculty of Pharmacy University of Belgrade  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7255-9079","authenticated-orcid":false,"given":"Magnus","family":"Ingelman\u2010Sundberg","sequence":"additional","affiliation":[{"name":"Section of Pharmacogenetics, Department of Physiology and Pharmacology Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"e_1_2_10_1_1","unstructured":"Table of Pharmacogenetic Associations. <https:\/\/www.fda.gov\/medical\u2010devices\/precision\u2010medicine\/table\u2010pharmacogenetic\u2010associations#section1>."},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.258"},{"key":"e_1_2_10_3_1","first-page":"1","article-title":"Pharmacogenomic prescribing guidelines: are they always useful?","volume":"0","author":"Ingelman\u2010Sundberg M.","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.011"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"e_1_2_10_6_1","unstructured":"Pharmacogene Variation Consortium. <https:\/\/www.pharmvar.org\/>."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8020015"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-14-RG-014"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.52.6.1034"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2021-0093"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf3637"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666140202215316"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3255"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-024-03721-6"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2246"},{"key":"e_1_2_10_16_1","unstructured":"CYPTAM study. <https:\/\/onderzoekmetmensen.nl\/en\/node\/23389\/pdf>."},{"key":"e_1_2_10_17_1","unstructured":"PharmGKB. <https:\/\/www.pharmgkb.org\/>."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(87)90006-6"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2571"},{"key":"e_1_2_10_20_1","unstructured":"LDLlink. <https:\/\/ldlink.nih.gov>."},{"key":"e_1_2_10_21_1","unstructured":"Ensembl. <www.ensembl.org>."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-022-01488-1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c00203"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M511232200"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000758"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)08211-X"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2846"},{"key":"e_1_2_10_28_1","unstructured":"CPIC guidelines. <https:\/\/cpicpgx.org\/guidelines\/>."},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2018.08.004"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12890"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30088-4"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500285"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081087"},{"key":"e_1_2_10_35_1","unstructured":"PharmFreq. <https:\/\/www.pharmfreq.com>."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01433-9"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:16:30Z","timestamp":1754723790000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/cpt.3680"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3680","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"2024-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}